Literature DB >> 24857075

50 Years of progress in the systemic therapy of non-small cell lung cancer.

Heather Wakelee1, Karen Kelly1, Martin J Edelman1.   

Abstract

Non-small cell lung cancer constitutes 85% to 90% of lung cancer and is the most common cause of cancer death. Over the past 50 years, substantial progress has been made in all aspects of lung cancer including screening, diagnostic evaluation, surgery, radiation therapy, and chemotherapy. This review focuses on the advances in systemic therapy during this half century.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24857075      PMCID： PMC5600272          DOI： 10.14694/EdBook_AM.2014.34.177

Source DB:  PubMed          Journal:  Am Soc Clin Oncol Educ Book        ISSN： 1548-8748


  93 in total

1.  A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group.

Authors:  S M Keller; S Adak; H Wagner; A Herskovic; R Komaki; B J Brooks; M C Perry; R B Livingston; D H Johnson
Journal:  N Engl J Med       Date:  2000-10-26       Impact factor: 91.245

2.  ROS1 rearrangements define a unique molecular class of lung cancers.

Authors:  Kristin Bergethon; Alice T Shaw; Sai-Hong Ignatius Ou; Ryohei Katayama; Christine M Lovly; Nerina T McDonald; Pierre P Massion; Christina Siwak-Tapp; Adriana Gonzalez; Rong Fang; Eugene J Mark; Julie M Batten; Haiquan Chen; Keith D Wilner; Eunice L Kwak; Jeffrey W Clark; David P Carbone; Hongbin Ji; Jeffrey A Engelman; Mari Mino-Kenudson; William Pao; A John Iafrate
Journal:  J Clin Oncol       Date:  2012-01-03       Impact factor: 44.544

3.  TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Authors:  Roy S Herbst; Diane Prager; Robert Hermann; Lou Fehrenbacher; Bruce E Johnson; Alan Sandler; Mark G Kris; Hai T Tran; Pam Klein; Xin Li; David Ramies; David H Johnson; Vincent A Miller
Journal:  J Clin Oncol       Date:  2005-07-25       Impact factor: 44.544

4.  Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324.

Authors:  George R Blumenschein; Rebecca Paulus; Walter J Curran; Francisco Robert; Frank Fossella; Maria Werner-Wasik; Roy S Herbst; Philip O Doescher; Hak Choy; Ritsuko Komaki
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

5.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.

Authors:  K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

6.  Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer.

Authors:  Luhua Wang; Shixiu Wu; Guangfei Ou; Nan Bi; Wenfeng Li; Hua Ren; Jianzhong Cao; Jun Liang; Junling Li; Zongmei Zhou; Jima Lv; Xiangru Zhang
Journal:  Lung Cancer       Date:  2012-03-13       Impact factor: 5.705

7.  Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab.

Authors:  David R Spigel; John D Hainsworth; Denise A Yardley; Eric Raefsky; Jeffrey Patton; Nancy Peacock; Cindy Farley; Howard A Burris; F Anthony Greco
Journal:  J Clin Oncol       Date:  2009-11-09       Impact factor: 44.544

8.  Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.

Authors:  Charles A Butts; Keyue Ding; Lesley Seymour; Philip Twumasi-Ankrah; Barbara Graham; David Gandara; David H Johnson; Kenneth A Kesler; Mark Green; Mark Vincent; Yvon Cormier; Glenwood Goss; Brian Findlay; Michael Johnston; Ming-Sound Tsao; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2009-11-23       Impact factor: 44.544

9.  Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

Authors:  Giuseppe Giaccone; Roy S Herbst; Christian Manegold; Giorgio Scagliotti; Rafael Rosell; Vincent Miller; Ronald B Natale; Joan H Schiller; Joachim Von Pawel; Anna Pluzanska; Ulrich Gatzemeier; John Grous; Judith S Ochs; Steven D Averbuch; Michael K Wolf; Pamela Rennie; Abderrahim Fandi; David H Johnson
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

10.  Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.

Authors:  Gerold Bepler; Charles Williams; Michael J Schell; Wei Chen; Zhong Zheng; George Simon; Shirish Gadgeel; Xiuhua Zhao; Fred Schreiber; Julie Brahmer; Alberto Chiappori; Tawee Tanvetyanon; Mary Pinder-Schenck; Jhanelle Gray; Eric Haura; Scott Antonia; Juergen R Fischer
Journal:  J Clin Oncol       Date:  2013-05-20       Impact factor: 44.544
View more
  46 in total

1.  Lung cancer combination therapy: doxorubicin and β-elemene co-loaded, pH-sensitive nanostructured lipid carriers.

Authors:  Chengsong Cao; Qun Wang; Yong Liu
Journal:  Drug Des Devel Ther       Date:  2019-04-05       Impact factor: 4.162

Review 2.  Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe.

Authors:  Ameen Abdulla Salahudeen; Manali I Patel; Paul Baas; Walter J Curran; Jeffrey D Bradley; David R Gandara; Glenwood D Goss; Tony S Mok; Suresh S Ramalingam; Everett E Vokes; Shakun M Malik; Heather A Wakelee
Journal:  Clin Lung Cancer       Date:  2016-06-27       Impact factor: 4.785

3.  Chemotherapy alters subjective senses of taste and smell but not dietary patterns in Japanese lung cancer patients.

Authors:  Nao Yoshimoto; Masaharu Inagaki; Yoshie Sekiguchi; Yoko Tomishima; Kayo Masuko
Journal:  Support Care Cancer       Date:  2019-07-08       Impact factor: 3.603

4.  Clinical significance of epithelial-mesenchymal transition-related molecules in lung adenocarcinoma.

Authors:  Y Zhang; L F Wang; J H Gao; L Li; P Jiang; X Lv; L X Yu; J Yang; R T Li; B R Liu
Journal:  Curr Oncol       Date:  2019-04-01       Impact factor: 3.677

5.  New lung cancer treatments (immunotherapy and targeted therapies) and their associations with depression and other psychological side effects as compared to chemotherapy.

Authors:  Daniel C McFarland
Journal:  Gen Hosp Psychiatry       Date:  2019-04-18       Impact factor: 3.238

6.  Berberine chloride suppresses non-small cell lung cancer by deregulating Sin3A/TOP2B pathway in vitro and in vivo.

Authors:  Jian Chen; Xiaofei Huang; Cheng Tao; Li Wang; Zide Chen; Xinping Li; Qiang Zeng; Min Ma; Ren Zhang; Zhengzhi Wu
Journal:  Cancer Chemother Pharmacol       Date:  2020-06-30       Impact factor: 3.333

7.  Co-delivery of etoposide and cisplatin in dual-drug loaded nanoparticles synergistically improves chemoradiotherapy in non-small cell lung cancer models.

Authors:  Maofan Zhang; C Tilden Hagan; Hayley Foley; Xi Tian; Feifei Yang; Kin Man Au; Yu Mi; Yusra Medik; Kyle Roche; Kyle Wagner; Zachary Rodgers; Yuanzeng Min; Andrew Z Wang
Journal:  Acta Biomater       Date:  2021-02-05       Impact factor: 10.633

8.  Development of a high-throughput and sensitive assay of fusion genes in lung cancer by array-based MALDI-TOFMS.

Authors:  Han-Tao Wu; Kun Li; Gang Wang; Xue-Xi Yang; Anna Zhu; Xu-Ping Xu; Ming Li; Ying-Song Wu; Tian-Cai Liu
Journal:  RSC Adv       Date:  2018-08-06       Impact factor: 4.036

9.  The efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis.

Authors:  Liang Zhou; Xi-Ling Wang; Qing-Long Deng; Yan-Qiu Du; Nai-Qing Zhao
Journal:  Sci Rep       Date:  2016-08-25       Impact factor: 4.379

10.  Characterization and selective incorporation of small non-coding RNAs in non-small cell lung cancer extracellular vesicles.

Authors:  Chuang Li; Fang Qin; Fen Hu; Hui Xu; Guihong Sun; Guang Han; Tao Wang; Mingxiong Guo
Journal:  Cell Biosci       Date:  2018-01-10       Impact factor: 7.133
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.